{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:37:15Z","timestamp":1794875835444,"version":"4.9.1"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Ka 502\/16-1"],"award-info":[{"award-number":["Ka 502\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Ka 502\/19-1"],"award-info":[{"award-number":["Ka 502\/19-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["Longterm fellowship"],"award-info":[{"award-number":["Longterm fellowship"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["Longterm fellowship"],"award-info":[{"award-number":["Longterm fellowship"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\u03b3\u03b4 T cells play uniquely important roles in stress surveillance and immunity for infections and carcinogenesis. Human \u03b3\u03b4 T cells recognize and kill transformed cells independently of human leukocyte antigen (HLA) restriction, which is an essential feature of conventional \u03b1\u03b2 T cells. V\u03b39V\u03b42 \u03b3\u03b4 T cells, which prevail in the peripheral blood of healthy adults, are activated by microbial or endogenous tumor-derived pyrophosphates by a mechanism dependent on butyrophilin molecules. \u03b3\u03b4 T cells expressing other T cell receptor variable genes, notably V\u03b41, are more abundant in mucosal tissue. In addition to the T cell receptor, \u03b3\u03b4 T cells usually express activating natural killer (NK) receptors, such as NKp30, NKp44, or NKG2D which binds to stress-inducible surface molecules that are absent on healthy cells but are frequently expressed on malignant cells. Therefore, \u03b3\u03b4 T cells are endowed with at least two independent recognition systems to sense tumor cells and to initiate anticancer effector mechanisms, including cytokine production and cytotoxicity. In view of their HLA-independent potent antitumor activity, there has been increasing interest in translating the unique potential of \u03b3\u03b4 T cells into innovative cellular cancer immunotherapies. Here, we discuss recent developments to enhance the efficacy of \u03b3\u03b4 T cell-based immunotherapy. This includes strategies for in vivo activation and tumor-targeting of \u03b3\u03b4 T cells, the optimization of in vitro expansion protocols, and the development of gene-modified \u03b3\u03b4 T cells. It is equally important to consider potential synergisms with other therapeutic strategies, notably checkpoint inhibitors, chemotherapy, or the (local) activation of innate immunity.<\/jats:p>","DOI":"10.1038\/s41423-020-0504-x","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T09:04:04Z","timestamp":1595408644000},"page":"925-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":303,"title":["Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-7103","authenticated-orcid":false,"given":"Dieter","family":"Kabelitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9once","family":"Kouakanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-3806","authenticated-orcid":false,"given":"Christian","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7332-2225","authenticated-orcid":false,"given":"Shirin","family":"Kalyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"504_CR1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1084\/jem.171.5.1597","volume":"117","author":"CM Parker","year":"1990","unstructured":"Parker, C. M. et al. Evidence for extrathymic changes in the T cell receptor gamma\/delta repertoire. J. Exp. Med. 117, 1597\u20131612 (1990).","journal-title":"J. Exp. Med."},{"key":"504_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1189\/jlb.5A1213-650RR","volume":"96","author":"A Vasudev","year":"2014","unstructured":"Vasudev, A. et al. \u03b3\/\u03b4 T cell subsets in human aging using the classical \u03b1\/\u03b2 T cell model. J. Leukoc. Biol. 96, 647\u2013655 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41385-018-0016-5","volume":"11","author":"T Mayassi","year":"2018","unstructured":"Mayassi, T. & Jabri, B. Human intraepithelial lymphocytes. Mucosal Immunol. 11, 1281\u20131289 (2018).","journal-title":"Mucosal Immunol."},{"key":"504_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cvfa.2019.08.001","volume":"35","author":"M Guerra-Maupome","year":"2019","unstructured":"Guerra-Maupome, M., Slate, J. R. & McGill, J. L. Gamma delta T cell function in ruminants. Vet. Clin. North Am. Food Anim. Pr. 35, 453\u2013469 (2019).","journal-title":"Vet. Clin. North Am. Food Anim. Pr."},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","volume":"13","author":"P Vantourout","year":"2013","unstructured":"Vantourout, P. & Hayday, A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat. Rev. Immunol. 13, 88\u2013100 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"504_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/intimm\/9.8.1065","volume":"9","author":"T Hinz","year":"1997","unstructured":"Hinz, T. et al. Identification of the complete expressed human TCR V gamma repertoire by flow cytometry. Int. Immunol. 9, 1065\u20131072 (1997).","journal-title":"Int. Immunol."},{"key":"504_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/intimm\/10.8.1067","volume":"10","author":"D Wesch","year":"1998","unstructured":"Wesch, D., Hinz, T. & Kabelitz, D. Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals. Int. Immunol. 10, 1067\u20131075 (1998).","journal-title":"Int. Immunol."},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/eji.1830210429","volume":"21","author":"K Deusch","year":"1991","unstructured":"Deusch, K. et al. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma\/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. Eur. J. Immunol. 21, 1053\u20131059 (1991).","journal-title":"Eur. J. Immunol."},{"key":"504_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/cmi.2012.44","volume":"10","author":"S Kalyan","year":"2013","unstructured":"Kalyan, S. & Kabelitz, D. Defining the nature of human \u03b3\u03b4 T cells: a biographical sketch of the highly empathetic. Cell. Mol. Immunol. 10, 21\u201329 (2013).","journal-title":"Cell. Mol. Immunol."},{"key":"504_CR10","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","volume":"96","author":"V Groh","year":"1999","unstructured":"Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879\u20136884 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2013.00069","volume":"4","author":"K Hudspeth.","year":"2013","unstructured":"Hudspeth., K., Silva-Santos, B. & Mavilio, D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front. Immunol. 4, 69 (2013).","journal-title":"Front. Immunol."},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"e22892","DOI":"10.4161\/onci.22892","volume":"2","author":"DV Correia","year":"2013","unstructured":"Correia, D. V., Lopes, A. & Silva-Santos, B. Tumor cell recognition by \u03b3\u03b4 T lymphocytes: T-cell receptor vs. NK-Cell receptors. Oncoimmunology 2, e22892 (2013).","journal-title":"NK-Cell receptors. Oncoimmunology"},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3389\/fimmu.2018.00929","volume":"9","author":"AE Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es, A. E., Di Lorenzo, B. & Silva-Santos, B. Molecular Determinants of Target Cell Recognition by Human \u03b3\u03b4 T Cells. Front. Immunol. 9, 929 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-3083.2009.02290.x","volume":"70","author":"K Pietschmann","year":"2009","unstructured":"Pietschmann, K. et al. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes. Scand. J. Immunol. 70, 245\u2013255 (2009).","journal-title":"Scand. J. Immunol."},{"key":"504_CR15","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00018-011-0699-1","volume":"68","author":"D Wesch","year":"2011","unstructured":"Wesch, D., Peters, C., Oberg, H. H., Pietschmann, K. & Kabelitz, D. Modulation of gammadelta T cell responses by TLR ligands. Cell. Mol. Life Sci. 68, 2357\u20132370 (2011).","journal-title":"Cell. Mol. Life Sci."},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-3083.2007.01963.x","volume":"66","author":"P Wrobel","year":"2007","unstructured":"Wrobel, P. et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand. J. Immunol. 66, 320\u2013328 (2007).","journal-title":"Scand. J. Immunol."},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/10428190500051893","volume":"46","author":"V Kunzmann","year":"2005","unstructured":"Kunzmann, V. & Wilhelm, M. Anti-lymphoma effect of gammadelta T cells. Leuk. Lymphoma 46, 671\u2013680 (2005).","journal-title":"Leuk. Lymphoma"},{"key":"504_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"504_CR19","doi-asserted-by":"crossref","unstructured":"Kabelitz, D. & He, W. The multifunctionality of human Vgamma9Vdelta2 gammadelta T cells: clonal plasticity or distinct subsets? Scand. J. Immunol. 76, 213\u2013222 (2013).","DOI":"10.1111\/j.1365-3083.2012.02727.x"},{"key":"504_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/cimm.2001.1850","volume":"212","author":"D Wesch","year":"2001","unstructured":"Wesch, D., Glatzel, A. & Kabelitz, D. Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype. Cell. Immunol. 212, 110\u2013117 (2001).","journal-title":"Cell. Immunol."},{"key":"504_CR21","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.4049\/jimmunol.1000600","volume":"184","author":"KJ Ness-Schwickerath","year":"2010","unstructured":"Ness-Schwickerath, K. J., Jin, C. & Morita, C. T. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J. Immunol. 184, 7268\u20137280 (2010).","journal-title":"J. Immunol."},{"key":"504_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","volume":"118","author":"N Caccamo","year":"2011","unstructured":"Caccamo, N. et al. Differentiation, phenotype, and function of interleukin-17-producing human V\u03b39V\u03b42 T cells. Blood 118, 129\u2013138 (2011). (2011).","journal-title":"Blood"},{"key":"504_CR23","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.1073\/pnas.1607136113","volume":"113","author":"C Peters","year":"2016","unstructured":"Peters, C., H\u00e4sler, R., Wesch, D. & Kabelitz, D. Human Vdelta2 T cells are a major source of interleukin-9. Proc. Natl Acad. Sci. USA 113, 12520\u201312525 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0014-5793(01)03191-X","volume":"509","author":"M Hintz","year":"2001","unstructured":"Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett. 509, 317\u2013322 (2001).","journal-title":"FEBS Lett."},{"key":"504_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.4049\/jimmunol.1600913","volume":"197","author":"PT Nerdal","year":"2016","unstructured":"Nerdal, P. T. et al. Butyrophilin 3A\/CD277-dependent activation of human gammadelta T cells: accessory cell capacity of distinct leukocyte populations. J. Immunol. 197, 3059\u20133068 (2016).","journal-title":"J. Immunol."},{"key":"504_CR26","doi-asserted-by":"publisher","first-page":"18337","DOI":"10.1074\/jbc.M100495200","volume":"276","author":"E Espinosa","year":"2001","unstructured":"Espinosa, E. et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J. Biol. Chem. 276, 18337\u201318344 (2001).","journal-title":"J. Biol. Chem."},{"key":"504_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","volume":"148","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244\u2013258 (2012).","journal-title":"Cell"},{"key":"504_CR28","doi-asserted-by":"publisher","first-page":"e953410","DOI":"10.4161\/21624011.2014.953410","volume":"3","author":"G Gruenbacher","year":"2014","unstructured":"Gruenbacher, G. et al. Stress-related and homeostatic cytokines regulate V\u03b39V\u03b42 T-cell surveillance of mevalonate metabolism. Oncoimmunology 3, e953410 (2014).","journal-title":"Oncoimmunology"},{"key":"504_CR29","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3389\/fimmu.2017.01714","volume":"8","author":"G Gruenbacher","year":"2017","unstructured":"Gruenbacher, G. & Thurnher, M. Mevalonate Metabolism in Immuno-Oncology. Front. Immunol. 8, 1714 (2017).","journal-title":"Front. Immunol."},{"key":"504_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober, H. J. et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163\u2013168 (2003).","journal-title":"J. Exp. Med."},{"key":"504_CR31","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","volume":"120","author":"C Harly","year":"2012","unstructured":"Harly, C. et al. Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset. Blood 120, 2269\u20132279 (2012).","journal-title":"Blood"},{"key":"504_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","volume":"40","author":"A Sandstrom","year":"2014","unstructured":"Sandstrom, A. et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V\u03b39V\u03b42 T cells. Immunity 40, 490\u2013500 (2014).","journal-title":"Immunity"},{"key":"504_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.02.016","volume":"50","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated V\u03b39V\u03b42 T cell activation. Immunity 50, 1043\u20131053 (2019).","journal-title":"Immunity"},{"key":"504_CR34","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.celrep.2016.04.081","volume":"15","author":"Z Sebestyen","year":"2016","unstructured":"Sebestyen, Z. et al. RhoB mediates phosphoantigen recognition by V\u03b39V\u03b42 T cell receptor. Cell Rep. 15, 1973\u20131985 (2016).","journal-title":"Cell Rep."},{"key":"504_CR35","doi-asserted-by":"crossref","unstructured":"Rigau, M. et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells. Science. 367, eaay5516 (2020).","DOI":"10.1126\/science.aay5516"},{"key":"504_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.immuni.2020.02.014","volume":"52","author":"MM Karunakaran","year":"2020","unstructured":"Karunakaran, M. M. et al. Butyrophilin-2A1 directly binds germline-encoded regions of the V\u03b39V\u03b42 TCR and is essential for phosphoantigen sensing. Immunity 52, 487\u2013498 (2020).","journal-title":"Immunity"},{"key":"504_CR37","doi-asserted-by":"publisher","unstructured":"Vyborova, A. et al. \u03b39\u03b42T cell diversity and the receptor interface with tumor cells. J. Clin. Invest. 132489. https:\/\/doi.org\/10.1172\/JCI132489 (2020).","DOI":"10.1172\/JCI132489"},{"key":"504_CR38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/cells9061433","volume":"9","author":"T Herrmann","year":"2020","unstructured":"Herrmann, T., Fichtner, A. S. & Karunakaran, M. M. The molecular basis of recognition of phosphoantigens by human V\u03b39V\u03b42 T cells. Cells 9, 1433 (2020).","journal-title":"Cells"},{"key":"504_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.immuni.2004.11.012","volume":"22","author":"E Scotet","year":"2005","unstructured":"Scotet, E. et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22, 71\u201380 (2005).","journal-title":"Immunity"},{"key":"504_CR40","doi-asserted-by":"publisher","first-page":"19242","DOI":"10.1074\/jbc.M112.349936","volume":"287","author":"C Mo","year":"2012","unstructured":"Mo, C., Dai, Y., Kang, N., Cui, L. & He, W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J. Biol. Chem. 287, 19242\u201319254 (2012).","journal-title":"J. Biol. Chem."},{"key":"504_CR41","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1074\/jbc.M111.327650","volume":"287","author":"Y Dai","year":"2012","unstructured":"Dai, Y., Chen, H., Mo, C., Cui, L. & He, W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human \u03b3\u03b4 T cells to induce innate anti-tumor\/virus immunity. J. Biol. Chem. 287, 16812\u201316819 (2012).","journal-title":"J. Biol. Chem."},{"key":"504_CR42","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1172\/JCI5409","volume":"103","author":"J D\u00e9chanet","year":"1999","unstructured":"D\u00e9chanet, J. et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J. Clin. Invest. 103, 1437\u20131449 (1999).","journal-title":"J. Clin. Invest."},{"key":"504_CR43","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.20041851","volume":"201","author":"F Halary","year":"2005","unstructured":"Halary, F. et al. Shared reactivity of V\u03b42neg \u03b3\u03b4 T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J. Exp. Med. 201, 1567\u20131578 (2005).","journal-title":"J. Exp. Med."},{"key":"504_CR44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ni.2394","volume":"13","author":"CR Willcox","year":"2012","unstructured":"Willcox, C. R. et al. Cytomegalovirus and tumor stress surveillance by binding of a human \u03b3\u03b4 T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13, 872\u2013879 (2012).","journal-title":"Nat. Immunol."},{"key":"504_CR45","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1073\/pnas.1621052114","volume":"114","author":"R Marlin","year":"2017","unstructured":"Marlin, R. et al. Sensing of cell stress by human \u03b3\u03b4 TCR-dependent recognition of annexin A2. Proc. Natl Acad. Sci. USA 114, 3163\u20133168 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cell.2016.08.030","volume":"167","author":"DiMarco Barros","year":"2016","unstructured":"Barros, Di. Marco et al. A. epithelia use butyrophilin-like molecules to shape organ-specific \u03b3\u03b4 T cell compartments. Cell 167, 203\u2013218 (2016).","journal-title":"Cell"},{"key":"504_CR47","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41590-018-0253-5","volume":"19","author":"D Melandri","year":"2018","unstructured":"Melandri, D. et al. The \u03b3\u03b4TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nat. Immunol. 19, 1352\u20131365 (2018).","journal-title":"Nat. Immunol."},{"key":"504_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.immuni.2019.09.006","volume":"51","author":"CR Willcox","year":"2019","unstructured":"Willcox, C. R. et al. Butyrophilin-like 3 directly binds a human V\u03b34+ T cell receptor using a modality distinct from clonally-restricted antigen. Immunity 51, 813\u2013825 (2019).","journal-title":"Immunity"},{"key":"504_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","volume":"296","author":"EJ Adams","year":"2015","unstructured":"Adams, E. J., Gu, S. & Luoma, A. M. Human gamma delta T cells: evolution and ligand recognition. Cell. Immunol. 296, 31\u201340 (2015).","journal-title":"Cell. Immunol."},{"key":"504_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4049\/jimmunol.1800934","volume":"203","author":"AC Hayday","year":"2019","unstructured":"Hayday, A. C. \u03b3\u03b4 T cell update: adaptate orchestrators of immune surveillance. J. Immunol. 203, 311\u2013320 (2019).","journal-title":"J. Immunol."},{"key":"504_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/cells9030772","volume":"9","author":"O Nussbaumer","year":"2020","unstructured":"Nussbaumer, O. & Thurnher, M. Functional phenotypes of human V\u03b39V\u03b42 T cells in lymphoid stress surveillance. Cells 9, 772 (2020).","journal-title":"Cells"},{"key":"504_CR52","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1126\/science.1063916","volume":"294","author":"M Girardi","year":"2001","unstructured":"Girardi, M. et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 294, 605\u2013609 (2001).","journal-title":"Science"},{"key":"504_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571\u2013580 (2008).","journal-title":"Immunity"},{"key":"504_CR54","first-page":"2064","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Role of NKG2D and its ligands in cancer immunotherapy. Am. J. Cancer Res. 9, 2064\u20132078 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"504_CR55","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.4049\/jimmunol.175.4.2144","volume":"175","author":"B Rincon-Orozco","year":"2005","unstructured":"Rincon-Orozco, B. et al. Activation of V gamma 9V delta 2 T cells by NKG2D. J. Immunol. 175, 2144\u20132151 (2005).","journal-title":"J. Immunol."},{"key":"504_CR56","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion [published correction appears in Nature. Nature 572, 254\u2013259 (2019).","journal-title":"Nature"},{"key":"504_CR57","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.4049\/jimmunol.169.3.1236","volume":"169","author":"J Wu","year":"2002","unstructured":"Wu, J., Groh, V. & Spies, T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J. Immunol. 169, 1236\u20131240 (2002).","journal-title":"J. Immunol."},{"key":"504_CR58","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1073\/pnas.1015433108","volume":"108","author":"B Xu","year":"2011","unstructured":"Xu, B. et al. Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc. Natl Acad. Sci. USA 108, 2414\u20132419 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR59","doi-asserted-by":"publisher","first-page":"e125884","DOI":"10.1172\/jci.insight.125884","volume":"4","author":"J Mikulak","year":"2019","unstructured":"Mikulak, J. et al. NKp46-expressing human gut-resident intraepithelial V\u03b41 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight 4, e125884 (2019).","journal-title":"JCI Insight"},{"key":"504_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"504_CR61","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"504_CR62","doi-asserted-by":"publisher","first-page":"e1284723","DOI":"10.1080\/2162402X.2017.1284723","volume":"6","author":"M Tosolini","year":"2017","unstructured":"Tosolini, M. et al. Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 6, e1284723 (2017).","journal-title":"Oncoimmunology"},{"key":"504_CR63","first-page":"1902880","volume":"7","author":"YR Miao","year":"2020","unstructured":"Miao, Y. R. et al. ImmuCellAI: a unique method for comprehensive t-cell subsets abundance prediction and its application in cancer. Immunother. Adv. Sci. 7, 1902880 (2020).","journal-title":"Immunother. Adv. Sci."},{"key":"504_CR64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jare.2020.03.009","volume":"24","author":"C Xu","year":"2020","unstructured":"Xu, C. et al. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. J. Adv. Res. 24, 139\u2013148 (2020).","journal-title":"J. Adv. Res"},{"key":"504_CR65","doi-asserted-by":"publisher","first-page":"e49878","DOI":"10.1371\/journal.pone.0049878","volume":"7","author":"A Cordova","year":"2012","unstructured":"Cordova, A. et al. Characterization of human \u03b3\u03b4 T lymphocytes infiltrating primary malignant melanomas. PLoS ONE 7, e49878 (2012).","journal-title":"PLoS ONE"},{"key":"504_CR66","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.pan.2016.07.008","volume":"16","author":"HH Oberg","year":"2016","unstructured":"Oberg, H. H. et al. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Pancreatology 16, 1069\u20131079 (2016).","journal-title":"Pancreatology"},{"key":"504_CR67","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fimmu.2019.00555","volume":"10","author":"M Lee","year":"2019","unstructured":"Lee, M. et al. Preferential infiltration of unique V\u03b39J\u03b32-V\u03b42 T cells into glioblastoma multiforme. Front. Immunol. 10, 555 (2019).","journal-title":"Front. Immunol."},{"key":"504_CR68","doi-asserted-by":"publisher","first-page":"e1347742","DOI":"10.1080\/2162402X.2017.1347742","volume":"6","author":"S Meraviglia","year":"2017","unstructured":"Meraviglia, S. et al. Distinctive features of tumor-infiltrating gammadelta T lymphocytes in human colorectal cancer. Oncoimmunology 6, e1347742 (2017).","journal-title":"Oncoimmunology"},{"key":"504_CR69","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7314\/APJCP.2014.15.2.775","volume":"15","author":"XY Cai","year":"2014","unstructured":"Cai, X. Y. et al. Low counts of \u03b3\u03b4 T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection. Asian Pac. J. Cancer Prev. 15, 775\u2013780 (2014).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"504_CR70","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/CBM-170026","volume":"20","author":"R Allaoui","year":"2017","unstructured":"Allaoui, R. et al. Infiltration of \u03b3\u03b4 T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer Biomark. 20, 395\u2013409 (2017).","journal-title":"Cancer Biomark."},{"key":"504_CR71","doi-asserted-by":"publisher","first-page":"E1537","DOI":"10.3390\/cells9061537","volume":"9","author":"G Chabab","year":"2020","unstructured":"Chabab, G. et al. Diversity of tumor-infiltrating \u03b3\u03b4 T cell abundance in solid cancers. Cells 9, E1537 (2020).","journal-title":"Cells"},{"key":"504_CR72","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/JLB.5MA1219-296R","volume":"107","author":"N Beucke","year":"2020","unstructured":"Beucke, N. et al. Pitfalls in the characterization of circulating and tissue-resident human \u03b3\u03b4 T cells. J. Leukoc. Biol. 107, 1097\u20131105 (2020).","journal-title":"J. Leukoc. Biol."},{"issue":"13 Suppl","key":"504_CR73","doi-asserted-by":"crossref","first-page":"Abstract nr 245","DOI":"10.1158\/1538-7445.AM2019-245","volume":"79","author":"S Rei\u00df","year":"2019","unstructured":"Rei\u00df, S. et al. Characterization and classification of glioblastoma multiforme using the novel multiparametric cyclic immunofluorescence analysis system MACSima. Cancer Res. 79(13 Suppl), Abstract nr 245 (2019).","journal-title":"Cancer Res."},{"key":"504_CR74","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-19-1159","volume":"26","author":"SY Yoo","year":"2020","unstructured":"Yoo, S. Y. et al. Whole-slide image analysis reveals quantitative landscape of tumor-immune microenvironment in colorectal cancers. Clin. Cancer Res. 26, 870\u2013881 (2020).","journal-title":"Clin. Cancer Res."},{"key":"504_CR75","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3748\/wjg.v22.i13.3573","volume":"22","author":"L Rong","year":"2016","unstructured":"Rong, L. et al. Analysis of tumor-infiltrating gamma delta T cells in rectal cancer. World J. Gastroenterol. 22, 3573\u20133580 (2016).","journal-title":"World J. Gastroenterol."},{"key":"504_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4111\/icu.2019.60.2.91","volume":"60","author":"M Vella","year":"2019","unstructured":"Vella, M. et al. Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. Investig. Clin. Urol. 60, 91\u201398 (2019).","journal-title":"Investig. Clin. Urol."},{"key":"504_CR77","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/JLB.5MA1119-265R","volume":"107","author":"HH Oberg","year":"2020","unstructured":"Oberg, H. H. et al. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. J. Leukoc. Biol. 107, 1081\u20131095 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"504_CR78","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/eji.200940157","volume":"40","author":"D Wakita","year":"2010","unstructured":"Wakita, D. et al. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927\u20131937 (2010).","journal-title":"Eur. J. Immunol."},{"key":"504_CR79","doi-asserted-by":"publisher","first-page":"E3562","DOI":"10.1073\/pnas.1403424111","volume":"111","author":"M Rei","year":"2014","unstructured":"Rei, M. et al. Murine CD27(-) V\u03b36(+) \u03b3\u03b4 T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc. Natl Acad. Sci. USA 111, E3562\u2013E3570 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR80","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"504_CR81","doi-asserted-by":"publisher","first-page":"E9056","DOI":"10.1073\/pnas.1700317114","volume":"114","author":"D Van Hede","year":"2017","unstructured":"Van Hede, D. et al. Human papillomavirus oncoproteins induce a reorganization of epithelial-associated \u03b3\u03b4 T cells promoting tumor formation. Proc. Natl Acad. Sci. USA 114, E9056\u2013E9065 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR82","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.12.040","volume":"176","author":"C Jin","year":"2019","unstructured":"Jin, C. et al. Commensal microbiota promote lung cancer development via \u03b3\u03b4 T cells. Cell 176, 998\u20131013 (2019).","journal-title":"Cell"},{"key":"504_CR83","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos, B., Mensurado, S. & Coffelt, S. B. \u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392\u2013404 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"504_CR84","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","volume":"40","author":"P Wu","year":"2014","unstructured":"Wu, P. et al. \u03b3\u03b4T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785\u2013800 (2014).","journal-title":"Immunity"},{"key":"504_CR85","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil, R. S. et al. IL17 producing \u03b3\u03b4T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int. J. Cancer 139, 869\u2013881 (2016).","journal-title":"Int. J. Cancer"},{"key":"504_CR86","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/2326-6066.CIR-16-0348","volume":"5","author":"E Lo Presti","year":"2017","unstructured":"Lo Presti, E. et al. Squamous cell tumors recruit \u03b3\u03b4 T cells producing either IL17 or IFN\u03b3 depending on the tumor stage. Cancer Immunol. Res. 5, 397\u2013407 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"504_CR87","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1158\/2326-6066.CIR-19-0513","volume":"8","author":"A Janssen","year":"2020","unstructured":"Janssen, A. et al. \u03b3\u03b4 T-cell receptors derived from breast cancer-infiltrating T lymphocytes mediate antitumor reactivity. Cancer Immunol. Res. 8, 530\u2013543 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"504_CR88","doi-asserted-by":"publisher","first-page":"E800","DOI":"10.3390\/cells9040800","volume":"9","author":"AS Fichtner","year":"2020","unstructured":"Fichtner, A. S., Ravens, S. & Prinz, I. Human \u03b3\u03b4 TCR repertoires in health and disease. Cells 9, E800 (2020).","journal-title":"Cells"},{"key":"504_CR89","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/cmi.2017.157","volume":"16","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. Profiling the pattern of the human T-cell receptor \u03b3\u03b4 complementary determinant region 3 repertoire in patients with lung carcinoma via high-throughput sequencing analysis. Cell. Mol. Immunol. 16, 250\u2013259 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"504_CR90","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","volume":"56","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi, H. et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56, 469\u2013476 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"504_CR91","first-page":"575","volume":"30","author":"H Kobayashi","year":"2010","unstructured":"Kobayashi, H., Tanaka, Y., Shimmura, H., Minato, N. & Tanabe, K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous \u03b3\u03b4 T-cells in a patient with renal cell carcinoma. Anticancer Res. 30, 575\u2013579 (2010).","journal-title":"Anticancer Res."},{"key":"504_CR92","first-page":"23","volume":"3","author":"K Kakimi","year":"2014","unstructured":"Kakimi, K., Matsushita, H., Murakawa, T. & Nakajima, J. \u03b3\u03b4 T cell therapy for the treatment of non-small cell lung cancer. Transl. Lung Cancer Res. 3, 23\u201333 (2014).","journal-title":"Transl. Lung Cancer Res."},{"key":"504_CR93","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","volume":"118","author":"DV Correia","year":"2011","unstructured":"Correia, D. V. et al. Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118, 992\u20131001 (2011).","journal-title":"Blood"},{"key":"504_CR94","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3109\/14653249.2011.553595","volume":"13","author":"GM Siegers","year":"2011","unstructured":"Siegers, G. M. et al. Human V\u03b41 \u03b3\u03b4 T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 13, 753\u2013764 (2011).","journal-title":"Cytotherapy"},{"key":"504_CR95","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/14653249.2012.700766","volume":"14","author":"A Knight","year":"2012","unstructured":"Knight, A., Mackinnon, S. & Lowdell, M. W. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 14, 1110\u20131118 (2012).","journal-title":"Cytotherapy"},{"key":"504_CR96","doi-asserted-by":"publisher","first-page":"e68729","DOI":"10.1371\/journal.pone.0068729","volume":"8","author":"A Knight","year":"2013","unstructured":"Knight, A. et al. CMV-independent lysis of glioblastoma by ex vivo expanded\/activated V\u03b41+ \u03b3\u03b4 T cells. PLoS ONE 8, e68729 (2013).","journal-title":"PLoS ONE"},{"key":"504_CR97","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida, A. R. et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795\u20135804 (2016).","journal-title":"Clin. Cancer Res."},{"key":"504_CR98","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","volume":"20","author":"DC Deniger","year":"2014","unstructured":"Deniger, D. C. et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin. Cancer Res. 20, 5708\u20135719 (2014).","journal-title":"Clin. Cancer Res."},{"key":"504_CR99","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.21873\/anticanres.12732","volume":"38","author":"Y Abe","year":"2018","unstructured":"Abe, Y. et al. Possible application of ascites-infiltrating gamma-delta T cells for adoptive immunotherapy. Anticancer Res. 38, 4327\u20134331 (2018).","journal-title":"Anticancer Res."},{"key":"504_CR100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/bs.mie.2019.07.019","volume":"631","author":"C Peters","year":"2020","unstructured":"Peters, C., Kouakanou, L., Oberg, H. H., Wesch, D. & Kabelitz, D. In vitro expansion of V\u03b39V\u03b42 T cells for immunotherapy. Methods Enzymol. 631, 223\u2013237 (2020).","journal-title":"Methods Enzymol."},{"key":"504_CR101","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.it.2017.06.004","volume":"38","author":"G Chitadze","year":"2017","unstructured":"Chitadze, G., Oberg, H. H., Wesch, D. & Kabelitz, D. The ambiguous role of \u03b3\u03b4 T lymphocytes in antitumor immunity. Trends Immunol. 38, 668\u2013678 (2017).","journal-title":"Trends Immunol."},{"key":"504_CR102","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.trecan.2017.06.003","volume":"3","author":"C Fleming","year":"2017","unstructured":"Fleming, C., Morrissey, S., Cai, Y. & Yan, J. \u03b3\u03b4 T cells: unexpected regulators of cancer development and progression. Trends Cancer 3, 561\u2013570 (2017).","journal-title":"Trends Cancer"},{"key":"504_CR103","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","volume":"166","author":"D Daley","year":"2016","unstructured":"Daley, D. et al. \u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation. Cell 166, 1485\u20131499 (2016).","journal-title":"Cell"},{"key":"504_CR104","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","volume":"27","author":"G Peng","year":"2007","unstructured":"Peng, G. et al. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27, 334\u2013348 (2007).","journal-title":"Immunity"},{"key":"504_CR105","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/JLB.3MA0420-278RR","volume":"107","author":"G Chabab","year":"2020","unstructured":"Chabab, G. et al. Identification of a regulatory Vd1 gamma delta T cell population expressing CD73 in human breast cancer. J. Leukoc. Biol. 107, 1057\u20131067 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"504_CR106","first-page":"513","volume":"11","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. An innate-like V\u03b41+ \u03b3\u03b4 T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci. Transl. Med. 11, 513 (2019).","journal-title":"Sci. Transl. Med."},{"key":"504_CR107","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.it.2016.08.012","volume":"37","author":"M Kanamori","year":"2016","unstructured":"Kanamori, M., Nakatsukasa, H., Okada, M., Lu, Q. & Yoshimura, A. Induced regulatory T cells: their development, stability, and applications. Trends Immunol. 37, 803\u2013811 (2016).","journal-title":"Trends Immunol."},{"key":"504_CR108","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.4049\/jimmunol.0901334","volume":"183","author":"R Casetti","year":"2009","unstructured":"Casetti, R. et al. Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J. Immunol. 183, 3574\u20133577 (2009).","journal-title":"J. Immunol."},{"key":"504_CR109","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1084\/jem.20151438","volume":"213","author":"X Yue","year":"2016","unstructured":"Yue, X. et al. Control of Foxp3 stability through modulation of TET activity. J. Exp. Med. 213, 377\u2013397 (2016).","journal-title":"J. Exp. Med."},{"key":"504_CR110","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/dxx049","volume":"29","author":"K Someya","year":"2017","unstructured":"Someya, K. et al. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation. Int. Immunol. 29, 365\u2013375 (2017).","journal-title":"Int. Immunol."},{"key":"504_CR111","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.4049\/jimmunol.1502352","volume":"196","author":"V Sasidharan Nair","year":"2016","unstructured":"Sasidharan Nair, V., Song, M. H. & Oh, K. I. Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner. J. Immunol. 196, 2119\u20132131 (2016).","journal-title":"J. Immunol."},{"key":"504_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63572-w","volume":"10","author":"L Kouakanou","year":"2020","unstructured":"Kouakanou, L. et al. Vitamin C supports conversion of human \u03b3\u03b4 T cells into FOXP3-expressing regulatory cells by epigenetic regulation. Sci. Rep. 10, 6550 (2020).","journal-title":"Sci. Rep."},{"key":"504_CR113","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00018-013-1467-1","volume":"71","author":"C Peters","year":"2014","unstructured":"Peters, C., Oberg, H. H., Kabelitz, D. & Wesch, D. Phenotype and regulation of immunosuppressive V\u03b42-expressing \u03b3\u03b4 T cells. Cell. Mol. Life Sci. 71, 1943\u20131960 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"504_CR114","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00262-019-02469-8","volume":"69","author":"K Schilbach","year":"2020","unstructured":"Schilbach, K. et al. Suppressive activity of V\u03b42+ \u03b3\u03b4 T cells on \u03b1\u03b2 T cells is licensed by TCR signaling and correlates with signal strength. Cancer Immunol. Immunother. 69, 593\u2013610 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"504_CR115","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2567.2008.02894.x","volume":"126","author":"V Kunzmann","year":"2009","unstructured":"Kunzmann, V., Kimmel, B., Herrmann, T., Einsele, H. & Wilhelm, M. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology 126, 256\u2013267 (2009).","journal-title":"Immunology"},{"key":"504_CR116","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jhep.2012.12.015","volume":"58","author":"Y Yi","year":"2013","unstructured":"Yi, Y. et al. The functional impairment of HCC-infiltrating \u03b3\u03b4 T cells, partially mediated by regulatory T cells in a TGF\u03b2- and IL-10-dependent manner. J. Hepatol. 58, 977\u2013983 (2013).","journal-title":"J. Hepatol."},{"key":"504_CR117","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/eji.201344195","volume":"44","author":"S Kalyan","year":"2014","unstructured":"Kalyan, S. & Kabelitz, D. When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential. Eur. J. Immunol. 44, 627\u2013633 (2014).","journal-title":"Eur. J. Immunol."},{"key":"504_CR118","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/eji.201343664","volume":"44","author":"F Sabbione","year":"2014","unstructured":"Sabbione, F. et al. Neutrophils suppress \u03b3\u03b4 T-cell function. Eur. J. Immunol. 44, 819\u2013830 (2014).","journal-title":"Eur. J. Immunol."},{"key":"504_CR119","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s00018-013-1495-x","volume":"71","author":"S Kalyan","year":"2014","unstructured":"Kalyan, S., Chandrasekaran, V., Quabius, E. S., Lindhorst, T. K. & Kabelitz, D. Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood \u03b3\u03b4 T cells. Cell. Mol. Life Sci. 71, 2335\u20132346 (2014).","journal-title":"Cell. Mol. Life Sci."},{"key":"504_CR120","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","volume":"144","author":"AJ Roelofs","year":"2009","unstructured":"Roelofs, A. J. et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP. Br. J. Haematol. 144, 245\u2013250 (2009).","journal-title":"Br. J. Haematol."},{"key":"504_CR121","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/sji.12221","volume":"80","author":"J Fazio","year":"2014","unstructured":"Fazio, J., Kalyan, S., Wesch, D. & Kabelitz, D. Inhibition of human \u03b3\u03b4 T cell proliferation and effector functions by neutrophil serine proteases. Scand. J. Immunol. 80, 381\u2013389 (2014).","journal-title":"Scand. J. Immunol."},{"key":"504_CR122","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/imm.12835","volume":"153","author":"NY Towstyka","year":"2018","unstructured":"Towstyka, N. Y. et al. Modulation of \u03b3\u03b4 T-cell activation by neutrophil elastase. Immunology 153, 225\u2013237 (2018).","journal-title":"Immunology"},{"key":"504_CR123","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3389\/fimmu.2019.01690","volume":"10","author":"HH Oberg","year":"2019","unstructured":"Oberg, H. H., Wesch, D., Kalyan, S. & Kabelitz, D. Regulatory interactions between neutrophils, tumor cells and T cells. Front. Immunol. 10, 1690 (2019).","journal-title":"Front. Immunol."},{"key":"504_CR124","doi-asserted-by":"publisher","first-page":"e2004990","DOI":"10.1371\/journal.pbio.2004990","volume":"16","author":"S Mensurado","year":"2018","unstructured":"Mensurado, S. et al. Tumor-associated neutrophils suppress pro-tumoral IL-17+ \u03b3\u03b4 T cells through induction of oxidative stress. PLoS Biol. 16, e2004990 (2018).","journal-title":"PLoS Biol."},{"key":"504_CR125","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3389\/fimmu.2018.02783","volume":"9","author":"AC Belkina","year":"2018","unstructured":"Belkina, A. C. et al. Multivariate computational analysis of gamma delta t cell inhibitory receptor signatures reveals the divergence of healthy and ART-suppressed HIV+ Aging. Front. Immunol. 9, 2783 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR126","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"DH Munn","year":"2016","unstructured":"Munn, D. H. & Mellor, A. L. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 37, 193\u2013207 (2016).","journal-title":"Trends Immunol."},{"key":"504_CR127","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/ijms19020430","volume":"19","author":"FC Chou","year":"2018","unstructured":"Chou, F. C., Chen, H. Y., Kuo, C. C. & Sytwu, H. K. Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 19, 430 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"504_CR128","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"504_CR129","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","volume":"1224","author":"M Dysthe","year":"2020","unstructured":"Dysthe, M. & Parihar, R. Myeloid-derived suppressor cells in the tumor microenvironment. Adv. Exp. Med. Biol. 1224, 117\u2013140 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"504_CR130","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/cmi.2015.07","volume":"13","author":"Y Mao","year":"2016","unstructured":"Mao, Y. et al. A new effect of IL-4 on human \u03b3\u03b4 T cells: promoting regulatory V\u03b41 T cells via IL-10 production and inhibiting function of V\u03b42 T cells. Cell. Mol. Immunol. 13, 217\u2013228 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"504_CR131","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3389\/fimmu.2018.01271","volume":"9","author":"A Sacchi","year":"2018","unstructured":"Sacchi, A. et al. Myeloid-derived suppressor cells specifically suppress IFN-\u03b3 production and antitumor cytotoxic activity of V\u03b42 T cells. Front. Immunol. 9, 1271 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR132","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann, V., Bauer, E. & Wilhelm, M. Gamma\/delta T-cell stimulation by pamidronate. N. Engl. J. Med. 340, 737\u2013738 (1999).","journal-title":"N. Engl. J. Med."},{"key":"504_CR133","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fimmu.2018.00800","volume":"9","author":"T Hoeres","year":"2018","unstructured":"Hoeres, T., Smetak, M., Pretscher, D. & Wilhelm, M. Improving the efficiency of V\u03b39V\u03b42 T-cell immunotherapy in cancer. Front. Immunol. 9, 800 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR134","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","volume":"1","author":"O Nussbaumer","year":"2019","unstructured":"Nussbaumer, O. & Koslowski, M. The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy. Immuno-Oncol. Technol. 1, 3\u201310 (2019).","journal-title":"Immuno-Oncol. Technol."},{"key":"504_CR135","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen, Z., Prinz, I., D\u00e9chanet-Merville, J., Silva-Santos, B. & Kuball, J. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19, 169\u2013184 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"504_CR136","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/cells9051206","volume":"9","author":"Y Liu","year":"2020","unstructured":"Liu, Y. & Zhang, C. The role of human gamma delta T cells in anti-tumor immunity and their potential for cancer immunotherapy. Cells 9, 1206 (2020).","journal-title":"Cells"},{"key":"504_CR137","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","volume":"15","author":"M Schumm","year":"2013","unstructured":"Schumm, M. et al. Depletion of T-cell receptor alpha\/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 15, 1253\u20131258 (2013).","journal-title":"Cytotherapy"},{"key":"504_CR138","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli, F. et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion. Blood 130, 677\u2013685 (2017).","journal-title":"Blood"},{"key":"504_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-45","volume":"12","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm, M. et al. Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells. J. Transl. Med. 12, 45 (2014).","journal-title":"J. Transl. Med."},{"key":"504_CR140","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1182\/bloodadvances.2019032409","volume":"3","author":"GJJ Kierkels","year":"2019","unstructured":"Kierkels, G. J. J. et al. Identification of a tumor-specific allo-HLA-restricted \u03b3\u03b4TCR. Blood Adv. 3, 2870\u20132882 (2019).","journal-title":"Blood Adv."},{"key":"504_CR141","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","volume":"7","author":"M Alnaggar","year":"2019","unstructured":"Alnaggar, M. et al. Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J. Immunother. Cancer 7, 36 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"504_CR142","doi-asserted-by":"publisher","first-page":"e01080","DOI":"10.1002\/cti2.1080","volume":"8","author":"M Raverdeau","year":"2019","unstructured":"Raverdeau, M., Cunningham, S. P., Harmon, C. & Lynch, L. \u03b3\u03b4 T cells in cancer: a small population of lymphocytes with big implications. Clin. Transl. Immunol. 8, e01080 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"504_CR143","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fimmu.2020.00992","volume":"11","author":"N Joalland","year":"2020","unstructured":"Joalland, N. & Scotet, E. Emerging challenges of preclinical models of anti-tumor immunotherapeutic strategies utilizing V\u03b39V\u03b42 T cells. Front. Immunol. 11, 992 (2020).","journal-title":"Front. Immunol."},{"key":"504_CR144","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.3389\/fimmu.2019.02717","volume":"10","author":"VA Polito","year":"2019","unstructured":"Polito, V. A. et al. Universal ready-to-use immunotherapeutic approach for the treatment of cancer: expanded and activated polyclonal \u03b3\u03b4 memory T cells. Front. Immunol. 10, 2717 (2019).","journal-title":"Front. Immunol."},{"key":"504_CR145","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.4049\/jimmunol.173.11.6767","volume":"173","author":"D Kabelitz","year":"2004","unstructured":"Kabelitz, D., Wesch, D., Pitters, E. & Zoller, M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J. Immunol. 173, 6767\u20136776 (2004).","journal-title":"J. Immunol."},{"key":"504_CR146","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","volume":"26","author":"Z Xiang","year":"2014","unstructured":"Xiang, Z. et al. Targeted activation of human V\u03b39V\u03b42-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 26, 565\u2013576 (2014).","journal-title":"Cancer Cell."},{"key":"504_CR147","doi-asserted-by":"publisher","first-page":"e1168554","DOI":"10.1080\/2162402X.2016.1168554","volume":"5","author":"U Jarry","year":"2016","unstructured":"Jarry, U. et al. Stereotaxic administrations of allogeneic human V\u03b39V\u03b42 T cells efficiently control the development of human glioblastoma brain tumors. Oncoimmunology 5, e1168554 (2016).","journal-title":"Oncoimmunology"},{"key":"504_CR148","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40425-017-0209-6","volume":"5","author":"MH Nada","year":"2017","unstructured":"Nada, M. H., Wang, H., Workalemahu, G., Tanaka, Y. & Morita, C. T. Enhancing adoptive cancer immunotherapy with V\u03b32V\u03b42 T cells through pulse zoledronate stimulation. J. Immunother. Cancer 5, 9 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"504_CR149","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1818488116","volume":"116","author":"G Pizzolato","year":"2019","unstructured":"Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes. Proc. Natl Acad. Sci. USA 116, 11906\u201311915 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"504_CR150","doi-asserted-by":"publisher","first-page":"e992749","DOI":"10.4161\/2162402X.2014.992749","volume":"4","author":"D Wu","year":"2015","unstructured":"Wu, D. et al. Ex vivo expanded human circulating V\u03b41 \u03b3\u03b4T cells exhibit favorable therapeutic potential for colon cancer. Oncoimmunology 4, e992749 (2015).","journal-title":"Oncoimmunology"},{"key":"504_CR151","doi-asserted-by":"publisher","first-page":"e988460","DOI":"10.4161\/2162402X.2014.988460","volume":"4","author":"D Gonnermann","year":"2015","unstructured":"Gonnermann, D. et al. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against \u03b3\u03b4 T cell cytotoxicity. Oncoimmunology 4, e988460 (2015).","journal-title":"Oncoimmunology"},{"key":"504_CR152","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/cas.13491","volume":"109","author":"Y Tanaka","year":"2018","unstructured":"Tanaka, Y. et al. Expansion of human \u03b3\u03b4 T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Sci. 109, 587\u2013599 (2018). (2018).","journal-title":"Cancer Sci."},{"key":"504_CR153","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jcyt.2017.12.014","volume":"20","author":"L Xiao","year":"2018","unstructured":"Xiao, L. et al. Large-scale expansion of V\u03b39V\u03b42 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells. Cytotherapy 20, 420\u2013435 (2018).","journal-title":"Cytotherapy"},{"key":"504_CR154","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1002514","volume":"187","author":"B Castella","year":"2011","unstructured":"Castella, B. et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V\u03b39V\u03b42 T cells, \u03b1\u03b2 CD8+ T cells, regulatory T cells, and dendritic cells. J. Immunol. 187, 1578\u20131590 (2011).","journal-title":"J. Immunol."},{"key":"504_CR155","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2018.05.002","volume":"41","author":"HH Van Acker","year":"2018","unstructured":"Van Acker, H. H. et al. The role of the common gamma-chain family cytokines in \u03b3\u03b4 T cell-based anti-cancer immunotherapy. Cytokine Growth Factor Rev. 41, 54\u201364 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"504_CR156","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-016-0329-3","volume":"9","author":"HH Van Acker","year":"2016","unstructured":"Van Acker, H. H. et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J. Hematol. Oncol. 9, 101 (2016). (2016).","journal-title":"J. Hematol. Oncol."},{"key":"504_CR157","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.imbio.2010.09.012","volume":"216","author":"MP Correia","year":"2011","unstructured":"Correia, M. P., Costa, A. V., Uhrberg, M., Cardoso, E. M. & Arosa, F. A. IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology 216, 604\u2013612 (2011).","journal-title":"Immunobiology"},{"key":"504_CR158","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fimmu.2017.00892","volume":"8","author":"HH Van Acker","year":"2017","unstructured":"Van Acker, H. H., Capsomidis, A., Smits, E. L. & Van Tendeloo, V. F. CD56 in the immune system: more than a marker for cytotoxicity? Front. Immunol. 8, 892 (2017).","journal-title":"Front. Immunol."},{"key":"504_CR159","doi-asserted-by":"publisher","first-page":"e1522471","DOI":"10.1080\/2162402X.2018.1522471","volume":"8","author":"C Peters","year":"2018","unstructured":"Peters, C. et al. TGF-\u03b2 enhances the cytotoxic activity of V\u03b42 T cells. Oncoimmunology 8, e1522471 (2018).","journal-title":"Oncoimmunology"},{"key":"504_CR160","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1084\/jem.20061524","volume":"204","author":"A Le Floc\u2019h","year":"2007","unstructured":"Le Floc\u2019h, A. et al. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J. Exp. Med. 204, 559\u2013570 (2007).","journal-title":"J. Exp. Med."},{"key":"504_CR161","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/0008-5472.CAN-12-2569","volume":"73","author":"K Franciszkiewicz","year":"2013","unstructured":"Franciszkiewicz, K. et al. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res. 73, 617\u2013628 (2013).","journal-title":"Cancer Res."},{"key":"504_CR162","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb, J. R., Milne, K., Watson, P., Deleeuw, R. J. & Nelson, B. H. Tumor infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20, 434\u2013444 (2014).","journal-title":"Clin. Cancer Res."},{"key":"504_CR163","doi-asserted-by":"publisher","unstructured":"Zheng, N. & Lu, Y. Targeting the IL-9 pathway in cancer immunotherapy. Hum. Vaccin. Immunother. 1\u20138. https:\/\/doi.org\/10.1080\/21645515.2019.1710413. (2020).","DOI":"10.1080\/21645515.2019.1710413"},{"key":"504_CR164","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.3389\/fimmu.2019.03082","volume":"10","author":"FL Baker","year":"2020","unstructured":"Baker, F. L. et al. Systemic \u03b2-adrenergic receptor activation augments the ex vivo expansion and anti-tumor activity of V\u03b39V\u03b42 T-cells. Front. Immunol. 10, 3082 (2020).","journal-title":"Front. Immunol."},{"key":"504_CR165","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fcell.2019.00128","volume":"7","author":"T Lee Chong","year":"2019","unstructured":"Lee Chong, T., Ahearn, E. L. & Cimmino, L. Reprogramming the epigenome with vitamin C. Front. Cell. Dev. Biol. 7, 128 (2019).","journal-title":"Front. Cell. Dev. Biol."},{"key":"504_CR166","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/JLB.1MR1219-245R","volume":"107","author":"C Peters","year":"2020","unstructured":"Peters, C., Kouakanou, L. & Kabelitz, D. A comparative view on vitamin C effects on \u03b1\u03b2- versus \u03b3\u03b4 T-cell activation and differentiation. J. Leukoc. Biol. 107, 1009\u20131022 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"504_CR167","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41423-019-0247-8","volume":"17","author":"L Kouakanou","year":"2020","unstructured":"Kouakanou, L. et al. Vitamin C promotes the proliferation and effector functions of human \u03b3\u03b4 T cells. Cell. Mol. Immunol. 17, 462\u2013473 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"504_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12080","volume":"7","author":"T Dalessandri","year":"2016","unstructured":"Dalessandri, T., Crawford, G., Hayes, M., Castro Seoane, R. & Strid, J. IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin. Nat. Commun. 7, 12080 (2016).","journal-title":"Nat. Commun."},{"key":"504_CR169","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct. Target Ther. 4, 35 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"504_CR170","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty, R. et al. CAR T cell therapy: a new era for cancer treatment (Review). Oncol. Rep. 42, 2183\u20132195 (2019).","journal-title":"Oncol. Rep."},{"key":"504_CR171","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fimmu.2018.01409","volume":"9","author":"J Fisher","year":"2018","unstructured":"Fisher, J. & Anderson, J. Engineering approaches in human gamma delta T cells for cancer immunotherapy. Front. Immunol. 9, 1409 (2018). (2018).","journal-title":"Front. Immunol."},{"key":"504_CR172","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis, A. et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol. Ther. 26, 354\u2013365 (2018).","journal-title":"Mol. Ther."},{"key":"504_CR173","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4049\/jimmunol.1102654","volume":"188","author":"N Himoudi","year":"2012","unstructured":"Himoudi, N. et al. Human \u03b3\u03b4 T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J. Immunol. 188, 1708\u20131716 (2012).","journal-title":"J. Immunol."},{"key":"504_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3539-3","volume":"17","author":"DC Harrer","year":"2017","unstructured":"Harrer, D. C. et al. RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: a safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma. BMC Cancer 17, 551 (2017).","journal-title":"BMC Cancer"},{"key":"504_CR175","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1182\/blood-2012-05-432427","volume":"120","author":"C Gr\u00fcnder","year":"2012","unstructured":"Gr\u00fcnder, C. et al. \u03b39 and \u03b42CDR3 domains regulate functional avidity of T cells harboring \u03b39\u03b42TCRs. Blood 120, 5153\u20135162 (2012).","journal-title":"Blood"},{"key":"504_CR176","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","volume":"9","author":"T Straetemans","year":"2018","unstructured":"Straetemans, T. et al. GMP-grade manufacturing of T cells engineered to express a defined \u03b3\u03b4TCR. Front. Immunol. 9, 1062 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR177","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"504_CR178","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-015-1662-z","volume":"64","author":"L Pereboeva","year":"2015","unstructured":"Pereboeva, L., Harkins, L., Wong, S. & Lamb, L. S. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. Cancer Immunol. Immunother. 64, 551\u2013562 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"504_CR179","doi-asserted-by":"publisher","first-page":"e51805","DOI":"10.1371\/journal.pone.0051805","volume":"8","author":"LS Lamb Jr","year":"2013","unstructured":"Lamb, L. S. Jr et al. Engineered drug resistant \u03b3\u03b4 T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS ONE 8, e51805 (2013).","journal-title":"PLoS ONE"},{"key":"504_CR180","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","volume":"60","author":"JM Lang","year":"2011","unstructured":"Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol. Immunother. 60, 1447\u20131460 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"504_CR181","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","volume":"35","author":"V Kunzmann","year":"2012","unstructured":"Kunzmann, V. et al. Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial. J. Immunother. 35, 205\u2013213 (2012).","journal-title":"J. Immunother."},{"key":"504_CR182","doi-asserted-by":"publisher","first-page":"e4909","DOI":"10.1097\/MD.0000000000004909","volume":"95","author":"JG Pressey","year":"2016","unstructured":"Pressey, J. G. et al. In vivo expansion and activation of \u03b3\u03b4 T cells as immunotherapy for refractory neuroblastoma: A phase 1 study. Medicine 95, e4909 (2016).","journal-title":"Medicine"},{"key":"504_CR183","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli, F. et al. Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450\u20137457 (2007).","journal-title":"Cancer Res."},{"key":"504_CR184","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","volume":"161","author":"S Meraviglia","year":"2010","unstructured":"Meraviglia, S. et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290\u2013297 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"504_CR185","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/jbmr.1769","volume":"28","author":"S Kalyan","year":"2013","unstructured":"Kalyan, S., Quabius, E. S., Wiltfang, J., M\u00f6nig, H. & Kabelitz, D. Can peripheral blood \u03b3\u03b4 T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J. Bone Miner. Res. 28, 728\u2013735 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"504_CR186","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbmt.2018.02.023","volume":"24","author":"MA de Witte","year":"2018","unstructured":"de Witte, M. A. et al. Early reconstitution of NK and \u03b3\u03b4 T cells and its implication for the design of post-transplant immunotherapy. Biol. Blood Marrow Transplant. 24, 1152\u20131162 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"504_CR187","doi-asserted-by":"publisher","first-page":"e000208","DOI":"10.1136\/jitc-2019-000208","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting V\u03b42+ T cells activities after hematopoietic transplantation for blood malignancies. J. Immunother. Cancer 8, e000208 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"504_CR188","doi-asserted-by":"publisher","first-page":"e1216291","DOI":"10.1080\/2162402X.2016.1216291","volume":"6","author":"A Bertaina","year":"2016","unstructured":"Bertaina, A. et al. Zoledronic acid boosts \u03b3\u03b4 T-cell activity in children receiving \u03b1\u03b2+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor. Oncoimmunology 6, e1216291 (2016).","journal-title":"Oncoimmunology"},{"key":"504_CR189","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fimmu.2020.00699","volume":"11","author":"P Merli","year":"2020","unstructured":"Merli, P. et al. Immune modulation properties of zoledronic acid on TcR\u03b3\u03b4 T-lymphocytes after TcR\u03b1\u03b2\/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia. Front. Immunol. 11, 699 (2020).","journal-title":"Front. Immunol."},{"key":"504_CR190","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","volume":"56","author":"CJ Bell","year":"2015","unstructured":"Bell, C. J. et al. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J. Autoimmun. 56, 66\u201380 (2015).","journal-title":"J. Autoimmun."},{"key":"504_CR191","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00262-010-0879-0","volume":"59","author":"J Bennouna","year":"2010","unstructured":"Bennouna, J. et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors. Cancer Immunol. Immunother. 59, 1521\u20131530 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"504_CR192","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3389\/fimmu.2018.01601","volume":"9","author":"JL Blazquez","year":"2018","unstructured":"Blazquez, J. L., Benyamine, A., Pasero, C. & Olive, D. New insights into the regulation of \u03b3\u03b4 T cells by BTN3A and other BTN\/BTNL in tumor immunity. Front. Immunol. 9, 1601 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR193","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41587-020-0487-2","volume":"38","author":"K Garber","year":"2020","unstructured":"Garber, K. \u03b3\u03b4 T cells bring unconventional cancer-targeting to the clinic\u2013again. Nat. Biotechnol. 38, 389\u2013391 (2020).","journal-title":"Nat. Biotechnol."},{"key":"504_CR194","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cellimm.2015.04.009","volume":"296","author":"HH Oberg","year":"2015","unstructured":"Oberg, H. H. et al. \u03b3\u03b4 T cell activation by bispecific antibodies. Cell. Immunol. 296, 41\u201349 (2015).","journal-title":"Cell. Immunol."},{"key":"504_CR195","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","volume":"74","author":"HH Oberg","year":"2014","unstructured":"Oberg, H. H. et al. Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells. Cancer Res. 74, 1349\u20131360 (2014).","journal-title":"Cancer Res."},{"key":"504_CR196","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.clim.2016.06.012","volume":"169","author":"R de Bruin","year":"2016","unstructured":"de Bruin, R. et al. Highly specific and potently activating V\u03b39V\u03b42-T cell specific nanobodies for diagnostic and therapeutic applications. Clin. Immunol. 169, 128\u2013138 (2016).","journal-title":"Clin. Immunol."},{"key":"504_CR197","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"504_CR198","doi-asserted-by":"publisher","first-page":"e1375641","DOI":"10.1080\/2162402X.2017.1375641","volume":"7","author":"R de Bruin","year":"2017","unstructured":"de Bruin, R. et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V\u03b39V\u03b42-T cells. Oncoimmunology 7, e1375641 (2017).","journal-title":"Oncoimmunology"},{"key":"504_CR199","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168 (2019).","journal-title":"Front. Immunol."},{"key":"504_CR200","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4049\/jimmunol.1100681","volume":"187","author":"AH Capietto","year":"2011","unstructured":"Capietto, A. H., Martinet, L. & Fourni\u00e9, J. J. Stimulated \u03b3\u03b4 T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J. Immunol. 187, 1031\u20131108 (2011).","journal-title":"J. Immunol."},{"key":"504_CR201","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/CJI.0000000000000289","volume":"42","author":"T Hoeres","year":"2019","unstructured":"Hoeres, T. et al. Improving immunotherapy against B-cell malignancies using \u03b3\u03b4 T-cell-specific stimulation and therapeutic monoclonal antibodies. J. Immunother. 42, 331\u2013344 (2019).","journal-title":"J. Immunother."},{"key":"504_CR202","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/eji.201040959","volume":"41","author":"M Iwasaki","year":"2011","unstructured":"Iwasaki, M. et al. Expression and function of PD-1 in human \u03b3\u03b4 T cells that recognize phosphoantigens. Eur. J. Immunol. 41, 345\u2013355 (2011).","journal-title":"Eur. J. Immunol."},{"key":"504_CR203","doi-asserted-by":"publisher","first-page":"1550618","DOI":"10.1080\/2162402X.2018.1550618","volume":"8","author":"T Hoeres","year":"2018","unstructured":"Hoeres, T., Holzmann, E., Smetak, M., Birkmann, J. & Wilhelm, M. PD-1 signaling modulates interferon-\u03b3 production by Gamma Delta (\u03b3\u03b4) T-Cells in response to leukemia. Oncoimmunology 8, 1550618 (2018).","journal-title":"Oncoimmunology"},{"key":"504_CR204","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1172\/JCI132712","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin, M. et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J. Clin. Invest. 130, 2560\u20132569 (2020).","journal-title":"J. Clin. Invest."},{"key":"504_CR205","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1189\/jlb.0710413","volume":"89","author":"DF Angelini","year":"2011","unstructured":"Angelini, D. F. et al. NKG2A inhibits NKG2C effector functions of \u03b3\u03b4 T cells: implications in health and disease. J. Leukoc. Biol. 89, 75\u201384 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"504_CR206","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743 (2018).","journal-title":"Cell"},{"key":"504_CR207","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall, T. et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J. Immunother. Cancer 7, 263 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"504_CR208","doi-asserted-by":"publisher","first-page":"e65145","DOI":"10.1371\/journal.pone.0065145","volume":"8","author":"M Todaro","year":"2013","unstructured":"Todaro, M. et al. Chemotherapy sensitizes colon cancer initiating cells to V\u03b39V\u03b42 T cell-mediated cytotoxicity. PLoS ONE 8, e65145 (2013).","journal-title":"PLoS ONE"},{"key":"504_CR209","doi-asserted-by":"publisher","first-page":"e1093276","DOI":"10.1080\/2162402X.2015.1093276","volume":"5","author":"G Chitadze","year":"2015","unstructured":"Chitadze, G. et al. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human \u03b3\u03b4 T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. Oncoimmunology 5, e1093276 (2015).","journal-title":"Oncoimmunology"},{"key":"504_CR210","doi-asserted-by":"publisher","first-page":"e1649971","DOI":"10.1080\/2162402X.2019.1649971","volume":"8","author":"N Joalland","year":"2019","unstructured":"Joalland, N. et al. Combined chemotherapy and allogeneic human V\u03b39V\u03b42 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo. Oncoimmunology 8, e1649971 (2019).","journal-title":"Oncoimmunology"},{"key":"504_CR211","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","volume":"132","author":"I de Weerdt","year":"2018","unstructured":"de Weerdt, I. et al. Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood 132, 2260\u20132272 (2018).","journal-title":"Blood"},{"key":"504_CR212","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4155\/fmc-2017-0203","volume":"10","author":"Z Kej\u00edk","year":"2018","unstructured":"Kej\u00edk, Z. et al. Epigenetic agents in combined anticancer therapy. Future Med. Chem. 10, 1113\u20131130 (2018).","journal-title":"Future Med. Chem."},{"key":"504_CR213","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fimmu.2018.00377","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Valproic acid combined with zoledronate enhance \u03b3\u03b4 T cell-mediated cytotoxicity against osteosarcoma cells via the accumulation of mevalonate pathway intermediates. Front. Immunol. 9, 377 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR214","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fimmu.2019.00569","volume":"10","author":"J Bhat","year":"2019","unstructured":"Bhat, J. et al. Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human gamma\/delta T cells upon interaction with tumor cells. Front. Immunol. 10, 569 (2019).","journal-title":"Front. Immunol."},{"key":"504_CR215","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3389\/fimmu.2018.01239","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Decitabine enhances V\u03b39V\u03b42 T cell-mediated cytotoxic effects on osteosarcoma cells via the NKG2DL-NKG2D axis. Front. Immunol. 9, 1239 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR216","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3389\/fimmu.2018.00512","volume":"9","author":"J Bhat","year":"2018","unstructured":"Bhat, J., Kouakanou, L., Peters, C., Yin, Z. & Kabelitz, D. Immunotherapy with human gamma delta T cells-synergistic potential of epigenetic drugs? Front. Immunol. 9, 512 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR217","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 24, 589\u2013602 (2013).","journal-title":"Cancer Cell."},{"key":"504_CR218","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPA.0000000000001211","volume":"48","author":"A Suto","year":"2019","unstructured":"Suto, A. et al. Increase of tumor infiltrating \u03b3\u03b4 T-cells in pancreatic ductal adenocarcinoma through remodeling of the extracellular matrix by a hyaluronan synthesis suppressor, 4-methylumbelliferone. Pancreas 48, 292\u2013298 (2019).","journal-title":"Pancreas"},{"key":"504_CR219","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/cancers12020297","volume":"12","author":"N Javaid","year":"2020","unstructured":"Javaid, N. & Choi, S. Toll-like receptors from the perspective of cancer treatment. Cancers 12, 297 (2020).","journal-title":"Cancers"},{"key":"504_CR220","doi-asserted-by":"publisher","first-page":"E713","DOI":"10.3390\/cells9030713","volume":"9","author":"R Serrano","year":"2020","unstructured":"Serrano, R., Wesch, D. & Kabelitz, D. Activation of human \u03b3\u03b4 T cells: modulation by toll-like receptor 8 ligands and role of monocytes. Cells 9, E713 (2020).","journal-title":"Cells"},{"key":"504_CR221","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","volume":"12","author":"A Li","year":"2019","unstructured":"Li, A. et al. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J. Hematol. Oncol. 12, 35 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"504_CR222","first-page":"1193","volume":"53","author":"D Wang","year":"2018","unstructured":"Wang, D., Jiang, W., Zhu, F., Mao, X. & Agrawal, S. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Int. J. Oncol. 53, 1193\u20131203 (2018).","journal-title":"Int. J. Oncol."},{"key":"504_CR223","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-030-35582-1_5","volume":"1223","author":"KD McCall","year":"2020","unstructured":"McCall, K. D., Muccioli, M. & Benencia, F. Toll-like receptors signaling in the tumor microenvironment. Adv. Exp. Med. Biol. 1223, 81\u201397 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"504_CR224","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.bbrc.2019.11.107","volume":"522","author":"S Harabuchi","year":"2020","unstructured":"Harabuchi, S. et al. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. Biochem. Biophys. Res. Commun. 522, 408\u2013414 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"504_CR225","doi-asserted-by":"publisher","first-page":"E1140","DOI":"10.3390\/cells9051140","volume":"9","author":"H Jonescheit","year":"2020","unstructured":"Jonescheit, H. et al. Influence of indoleamine-2,3-dioxygenase and its metabolite kynurenine on \u03b3\u03b4 T cell cytotoxicity against ductal pancreatic adenocarcinoma cells. Cells 9, E1140 (2020).","journal-title":"Cells"},{"key":"504_CR226","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3389\/fimmu.2020.01328","volume":"11","author":"D Gonnermann","year":"2020","unstructured":"Gonnermann, D. et al. Galectin-3 released by pancreatic ductal adenocarcinoma suppresses \u03b3\u03b4 T-cell proliferation but not their cytotoxicity. Front. Immunol. 11, 1328 (2020).","journal-title":"Front. Immunol."},{"key":"504_CR227","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3389\/fimmu.2018.01367","volume":"9","author":"GM Siegers","year":"2018","unstructured":"Siegers, G. M., Dutta, I., Lai, R. & Postovit, L. M. Functional plasticity of gamma delta T cells and breast tumor targets in hypoxia. Front. Immunol. 9, 1367 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR228","doi-asserted-by":"publisher","first-page":"E430","DOI":"10.3390\/ijms19020430","volume":"9","author":"FC Chou","year":"2018","unstructured":"Chou, F. C., Chen, H. Y., Kuo, C. C. & Sytwu, H. K. Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 9, E430 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"504_CR229","doi-asserted-by":"publisher","first-page":"111719","DOI":"10.1016\/j.yexcr.2019.111719","volume":"386","author":"X Li","year":"2020","unstructured":"Li, X. et al. Tim-3 suppresses the killing effect of V\u03b39V\u03b42 T cells on colon cancer cells by reducing perforin and granzyme B expression. Exp. Cell Res. 386, 111719 (2020).","journal-title":"Exp. Cell Res."},{"issue":"13 Suppl","key":"504_CR230","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1158\/1538-7445.AM2019-1551","volume":"79","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. First in class immunotherapy targeting Galectin-9 promotes T-cell activation and anti-tumor response against pancreatic cancer and other solid tumors. Cancer Res. 79(13 Suppl), 1551 (2019).","journal-title":"Cancer Res."},{"key":"504_CR231","doi-asserted-by":"publisher","first-page":"e55185","DOI":"10.7554\/eLife.55185","volume":"9","author":"AR Lim","year":"2020","unstructured":"Lim, A. R., Rathmell, W. K. & Rathmell, J. C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife 9, e55185 (2020).","journal-title":"Elife"},{"key":"504_CR232","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3389\/fimmu.2018.00998","volume":"9","author":"S Varesano","year":"2018","unstructured":"Varesano, S., Zocchi, M. R. & Poggi, A. Zoledronate triggers V\u03b42 T cells to destroy and kill spheroids of colon carcinoma: quantitative image analysis of three-dimensional cultures. Front. Immunol. 9, 998 (2018).","journal-title":"Front. Immunol."},{"key":"504_CR233","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CJI.0000000000000043","volume":"37","author":"S Gundermann","year":"2014","unstructured":"Gundermann, S. et al. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic V\u03b39V\u03b42 T cells. J. Immunother. 37, 321\u2013330 (2014).","journal-title":"J. Immunother."},{"key":"504_CR234","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria, O. et al. Harnessing innate immunity in cancer therapy [published correction appears in Nature . Nature 574, 45\u201356 (2019).","journal-title":"Nature"},{"key":"504_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62735-z","volume":"10","author":"S Kalyan","year":"2020","unstructured":"Kalyan, S. et al. Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology. Sci. Rep. 10, 5901 (2020).","journal-title":"Sci. Rep."},{"key":"504_CR236","unstructured":"Kalyan, S., Bazett, M., Mullins, D. W. & Gunn, H. Novel Microbial-based Immunotherapy Approach Enables Application of Adoptive Cell Therapy for Solid Tumors by Enhancing Both Immune Access to Tumor Microenvironment and Cancer Cell Immunogenecity [abstract]. Fifth International Cancer Immunotherapy Conference \u201cTranslating Science into Survival\u201d. September 25\u201328, Paris, France: CRI-CIMT-EATI-AACR 2019 Abstract A055 (2019)."},{"key":"504_CR237","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1126\/scitranslmed.aay8707","volume":"12","author":"A Magr\u00ec","year":"2020","unstructured":"Magr\u00ec, A. et al. High-dose vitamin C enhances cancer immunotherapy. Sci. Transl. Med. 12, 532 (2020).","journal-title":"Sci. Transl. Med."},{"key":"504_CR238","doi-asserted-by":"publisher","first-page":"E977","DOI":"10.3390\/nu11050977","volume":"11","author":"GNY van Gorkom","year":"2019","unstructured":"van Gorkom, G. N. Y., Lookermans, E. L., Van Elssen, C. H. M. J. & Bos, G. M. J. The effect of vitamin C (Ascorbic Acid) in the treatment of patients with cancer: a systematic review. Nutrients 11, E977 (2019).","journal-title":"Nutrients"}],"updated-by":[{"DOI":"10.1038\/s41423-020-00537-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000}}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0504-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0504-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0504-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T19:48:37Z","timestamp":1667504917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0504-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":238,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-0504-x","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.K. is a member of the Scientific Advisory Board of Incysus Therapeutics, Inc.; Imcheck Therapeutics; Lava Therapeutics B.V.; and Qu Biologics, Inc. S.K. is the Scientific Director of Qu Biologics, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}